Provided by Tiger Trade Technology Pte. Ltd.

Immunic, Inc.

1.02
+0.07237.63%
Post-market: 1.020.00000.00%19:59 EST
Volume:3.78M
Turnover:3.79M
Market Cap:133.07M
PE:-1.31
High:1.05
Open:0.9477
Low:0.9430
Close:0.9477
52wk High:1.35
52wk Low:0.5062
Shares:130.46M
Float Shares:95.79M
Volume Ratio:1.74
T/O Rate:3.95%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7790
EPS(LYR):-1.0033
ROE:-1653.15%
ROA:-198.76%
PB:-19.94
PE(LYR):-1.02

Loading ...

Eqs-News: Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation Into Commercial-Stage Company

THOMSON REUTERS
·
Feb 13

Immunic Inc - Co-Founder and Chief Executive Officer Daniel Vitt and Board of Directors Will Begin a Search for a New CEO

THOMSON REUTERS
·
Feb 13

Immunic Inc: Proceeds of Financing Expected to Support Co's Transition From Research & Development-Focused Co Into Fully Integrated Commercial Entity

THOMSON REUTERS
·
Feb 13

Press Release: Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company

Dow Jones
·
Feb 13

Immunic Price Target Maintained With a $8.00/Share by HC Wainwright & Co.

Dow Jones
·
Feb 09

Immunic Unveils Positive Phase 2 CALLIPER Trial Data for Vidofludimus Calcium in Progressive Multiple Sclerosis

Reuters
·
Feb 04

Eqs-News: Immunic to Present Additional Phase 2 Calliper Trial Data for Vidofludimus Calcium at the Actrims Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

THOMSON REUTERS
·
Feb 04

Insider Traders Lose US$42k As Immunic Drops

Simply Wall St.
·
Jan 30

Immunic Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Jan 07

Immunic Inc. Faces Nasdaq Delisting Risk Over Continued Low Share Price

Reuters
·
Jan 07

Immunic Inc. Sets New CEO Pay Package for Duane Nash

Reuters
·
Jan 06

Immunic Inc. CEO to Join Evercore ISI Healthcare Conference Fireside Chat

Reuters
·
Nov 26, 2025

Immunic price target lowered to $8 from $10 at H.C. Wainwright

TIPRANKS
·
Nov 14, 2025

Immunic, Inc. : H.c. Wainwright Cuts Target Price to $8 From $10

THOMSON REUTERS
·
Nov 14, 2025

Immunic’s Promising Market Potential: Buy Rating Backed by Vidofludimus Calcium’s Efficacy, Safety, and Strategic Financial Path

TIPRANKS
·
Nov 14, 2025

Immunic Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Nov 13, 2025

Biotech Immunic's Q3 net loss widens

Reuters
·
Nov 13, 2025

Immunic reports Q3 EPS (13c), consensus (18c)

TIPRANKS
·
Nov 13, 2025

Immunic Q3 EPS $(0.13) Beats $(0.18) Estimate

Benzinga
·
Nov 13, 2025

Immunic Inc. reports third quarter net loss of $25.6 million

Reuters
·
Nov 13, 2025